GEMBIN 200 MG INJ. VIAL.

About

GEMBIN is an antimetabolite chemotherapy agent belonging to the class of nucleoside analogs. It works by interfering with DNA synthesis and repair, leading to cell death. Once inside the cell, gemcitabine is phosphorylated to its active diphosphate and triphosphate forms. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme essential for the synthesis of deoxyribonucleotides required for DNA replication. Gemcitabine triphosphate is incorporated into DNA strands, causing chain termination and inhibiting further DNA synthesis. This dual mechanism of action effectively disrupts the proliferation of rapidly dividing cancer cells, making it a broad-spectrum agent against various solid tumors.

Its cytotoxic effects are cell cycle-specific, primarily affecting cells in the S-phase and blocking the progression of cells through the G1/S boundary. GEMBIN is widely used in the treatment of several advanced cancers, either as a single agent or in combination with other chemotherapeutic drugs. Its ability to induce apoptosis and inhibit tumor growth has made it a cornerstone in the management of pancreatic, lung, breast, and ovarian cancers, offering significant therapeutic benefits to patients with these challenging malignancies.

Uses

• Treatment of locally advanced or metastatic pancreatic cancer.
• Treatment of locally advanced or metastatic non-small cell lung cancer.
• Treatment of metastatic breast cancer, often in combination with paclitaxel.
• Treatment of advanced ovarian cancer, often in combination with carboplatin.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and infusion schedule are determined by the patient's condition and specific cancer type.

Benefits

• Effective against a wide range of solid tumors.
• Can be used as monotherapy or in combination regimens.
• May improve survival and quality of life in advanced cancers.
• Well-established efficacy in pancreatic and lung cancers.
• Offers a valuable option for metastatic disease.
• Relatively manageable side effect profile compared to some other agents.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea and vomiting
• Fatigue/Asthenia
• Flu-like symptoms
• Rash
• Edema
• Elevated liver transaminases
• Proteinuria/Hematuria
• Dyspnea (shortness of breath)
• Alopecia (mild)
• Diarrhea
• Peripheral neuropathy (rare)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate liver toxicity or gastrointestinal side effects.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Effective contraception is required for both male and female patients.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; monitor liver function closely. Dose adjustments may be necessary.
• Kidney - Use with caution in patients with renal impairment; monitor kidney function closely. Dose adjustments may be necessary.
• Lung - Monitor for signs of pulmonary toxicity, including interstitial pneumonitis or acute respiratory distress syndrome.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.